Zobrazeno 1 - 10
of 25
pro vyhledávání: '"D H Huffman"'
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(7)
This Phase I study was designed to determine the maximally tolerated doses of paclitaxel (given as an outpatient 3-h infusion) plus carboplatin in advanced, untreated non-small cell lung cancer. Secondary objectives were to determine the response rat
Autor:
J E Coker, Danny D. Shen, D H Huffman, K M Hassanein, F L Atkins, W F Cathcart-Rake, Daniel L. Azarnoff
Publikováno v:
Circulation. 61:938-945
Sixteen healthy men were evaluated for left ventricular performance changes and beta-blockade after therapeutic oral doses of disopyramide and propranolol administered alone and concurrently. The volunteers were randomly assigned to receive one of tw
Autor:
D. H. Huffman
Publikováno v:
JAMA: The Journal of the American Medical Association. 222:957-960
Autor:
D H, Huffman
Publikováno v:
American journal of hospital pharmacy. 33(2)
The pharmacology of digitalis compounds is reviewed, and the clinical use of the cardiac glycosides is discussed with particular attention to the selection of patients for digitalis therapy and to a study of the usefulness of various methods to monit
Autor:
D H, Huffman, C E, Hignite
Publikováno v:
Clinical chemistry. 22(6)
Serum quinidine concentrations were determined in patients on chronic therapeutic doses. Although results were higher by a protein precipitate-fluorescence method as compared to a specific extraction fluorescence method, there was substantial correla
Autor:
D H, Huffman, C A, Dujovne
Publikováno v:
Research communications in chemical pathology and pharmacology. 15(1)
Autor:
D H, Huffman
Publikováno v:
The Laryngoscope. 88(1 Pt 2 Suppl 8)
Autor:
D H, Huffman
Publikováno v:
The Journal of the Maine Medical Association. 66(12)
Publikováno v:
Cancer research. 34(2)
Publikováno v:
Cancer research. 37(11)
The metabolism of antipyrine (10 mg/kg i.v.) was studied in nine patients with cancer of the lung and in a cancer-free control group matched for age, sex, drug intake, and smoking and drinking history. The mean plasma clearance of antipyrine was 0.04